Share:
WESTLAKE VILLAGE, Calif., April 19, 2021 (GLOBE NEWSWIRE) Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, will present new data from three studies evaluating the safety, efficacy, and tolerability of its once-daily, topical roflumilast cream and foam at the American Academy of Dermatology Virtual Meeting Experience (VMX) April 23 - 25, 2021. Patients suffering from plaque psoriasis, scalp psoriasis, and seborrheic dermatitis have significant unmet needs given the lack of efficacious, safe, tolerable topical options for long-term use, said Patrick Burnett, M.D., Ph.D., FAAD, Chief Medical Officer, Arcutis. We are pleased to share these new data that further reinforce the potential of roflumilast cream and foam in various inflammatory skin diseases. If approved by the FDA, our therap
Credit: Michael Bradshaw
Found around the world, powdery mildew is a fungal disease especially harmful to plants within the sunflower family. Like most invasive pathogens, powdery mildew is understudied and learning how it affects hosts can help growers make more informed decisions and protect their crops.
Scientists at the University of Washington and the University of Central Florida inoculated 126 species of plants in the sunflower family with powdery mildew, growing 500 plants from seeds that were collected from the wild and provided from the USDA germplasm network. Through this large-scale study, they were able to measure the various plants susceptibility to powdery mildew.
Day Five of Bionano s Next-Generation Cytogenomics Symposium: Saphyr Identifies Structural Variants that May Predispose to Severe COVID-19 Illness yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Could procalcitonin indicate bacterial co-infections in COVID-19 patients?
medRxiv preprint server.
Background
Since its emergence in December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of COVID-19, has already infected more than 92 million people and claimed about 2 million lives globally. Alike other respiratory infections, the presence of microbial co-infection can increase the disease severity and mortality in critically ill COVID-19 patients. To prevent adverse outcomes of microbial co-infection, empiric antibiotics are frequently used as a part of the standard of care treatment for in-hospital COVID-19 patients. However, several clinical studies have shown that the risk of bacterial co-infection in COVID-19 patients is lower compared to other viral infections.